🇺🇸 CC-10004 in United States
34 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 34
Most-reported reactions
- Pneumonia — 7 reports (20.59%)
- Pyrexia — 5 reports (14.71%)
- Abdominal Pain — 4 reports (11.76%)
- Abdominal Abscess — 3 reports (8.82%)
- Cholelithiasis — 3 reports (8.82%)
- Suicidal Ideation — 3 reports (8.82%)
- Transient Ischaemic Attack — 3 reports (8.82%)
- Abdominal Adhesions — 2 reports (5.88%)
- Acute Myocardial Infarction — 2 reports (5.88%)
- Adenocarcinoma Of Colon — 2 reports (5.88%)
Frequently asked questions
Is CC-10004 approved in United States?
CC-10004 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for CC-10004 in United States?
Amgen is the originator. The local marketing authorisation holder may differ — check the official source linked above.